Published in Clin Endocrinol (Oxf) on March 01, 2003
The osteoprotective effect of Herba epimedii (HEP) extract in vivo and in vitro. Evid Based Complement Alternat Med (2005) 1.16
Therapeutic effects of radix dipsaci, pyrola herb, and Cynomorium songaricum on bone metabolism of ovariectomized rats. BMC Complement Altern Med (2012) 0.90
The beneficial effect of Radix Dipsaci total saponins on bone metabolism in vitro and in vivo and the possible mechanisms of action. Osteoporos Int (2012) 0.88
Evidence-based assessment of antiosteoporotic activity of petroleum-ether extract of Cissus quadrangularis Linn. on ovariectomy-induced osteoporosis. Ups J Med Sci (2009) 0.86
Lactobacillus fermentation enhances the inhibitory effect of Hwangryun-haedok-tang in an ovariectomy-induced bone loss. BMC Complement Altern Med (2013) 0.80
The effects of Cosmos caudatus (ulam raja) on dynamic and cellular bone histomorphometry in ovariectomized rats. BMC Res Notes (2013) 0.78
Hormone replacement therapy: current controversies. Clin Endocrinol (Oxf) (2003) 0.77
32k Da protein improve ovariectomy-induced bone loss in rats. Prion (2013) 0.77
Low salivary testosterone levels in patients with breast cancer. BMC Cancer (2010) 0.76
Antiosteoporotic Effects of Huangqi Sanxian Decoction in Cultured Rat Osteoblasts by Proteomic Characterization of the Target and Mechanism. Evid Based Complement Alternat Med (2015) 0.75
Effects of total flavonoids from Drynariae Rhizoma prevent bone loss in vivo and in vitro. Bone Rep (2016) 0.75
Flavonoid glycosides isolated from Epimedium brevicornum and their estrogen biosynthesis-promoting effects. Sci Rep (2017) 0.75
Urinary incontinence in young nulligravid women: a cross-sectional analysis. Ann Intern Med (2012) 3.34
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
Incidence of total knee and hip replacement for osteoarthritis in relation to circulating sex steroid hormone concentrations in women. Arthritis Rheumatol (2014) 2.05
Sexual function after breast cancer. J Sex Med (2010) 1.89
Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years. Menopause (2015) 1.71
Endogenous androgen levels and cardiovascular risk profile in women across the adult life span. Menopause (2007) 1.70
Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause (2003) 1.62
The cross-sectional relationship between fortnightly exercise and knee cartilage properties in healthy adult women in midlife. Menopause (2007) 1.53
Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis. Menopause (2013) 1.41
Low use of effective and safe therapies for moderate to severe menopausal symptoms: a cross-sectional community study of Australian women. Menopause (2016) 1.38
A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder. Psychoneuroendocrinology (2005) 1.36
Treatment of menopausal symptoms: what shall we do now? Lancet (2005) 1.35
Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab (2006) 1.30
New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab (2003) 1.27
Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause (2006) 1.09
Prevalence and incidence of urinary incontinence in women: review of the literature and investigation of methodological issues. Int J Urol (2008) 1.06
Well-being, health-related quality of life and cardiovascular disease risk profile in women with subclinical thyroid disease - a community-based study. Clin Endocrinol (Oxf) (2007) 1.06
Sexual function in well women: stratification by sexual satisfaction, hormone use, and menopause status. J Sex Med (2008) 1.05
Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2014) 1.02
Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology (2010) 1.02
Estrogen regulates development of the somatic cell phenotype in the eutherian ovary. FASEB J (2002) 1.00
Age-specific prevalence of, and factors associated with, different types of urinary incontinence in community-dwelling Australian women assessed with a validated questionnaire. Maturitas (2009) 1.00
Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy. Menopause (2005) 0.99
Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev (2004) 0.99
Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women - a prospective cohort study. Arthritis Res Ther (2009) 0.98
Sexual function, incontinence, and wellbeing in women after rectal cancer--a review of the evidence. J Sex Med (2012) 0.95
Compartment differences in knee cartilage volume in healthy adults. J Rheumatol (2002) 0.95
DHEA therapy for women: effect on sexual function and wellbeing. Hum Reprod Update (2007) 0.94
Urinary incontinence is associated with lower psychological general well-being in community-dwelling women. Menopause (2010) 0.93
Differential expression of factors involved in fat metabolism with age and the menopause transition. Maturitas (2005) 0.92
Static knee alignment is associated with the risk of unicompartmental knee cartilage defects. J Orthop Res (2008) 0.91
Endocrine aspects of women's sexual function. J Sex Med (2010) 0.90
High sensitivity C-reactive protein is associated with lower tibial cartilage volume but not lower patella cartilage volume in healthy women at mid-life. Arthritis Res Ther (2008) 0.89
Greater superior than inferior parietal lobule activation with increasing rotation angle during mental rotation: an fMRI study. Neuropsychologia (2009) 0.89
Understanding discontinuation of oral adjuvant endocrine therapy by women with hormone receptor-positive invasive breast cancer nearly 4 years from diagnosis. Menopause (2013) 0.87
The natural history of bone marrow lesions in community-based middle-aged women without clinical knee osteoarthritis. Semin Arthritis Rheum (2008) 0.86
Negative beliefs about low back pain are associated with high pain intensity and high level disability in community-based women. BMC Musculoskelet Disord (2008) 0.86
The safety of 52 weeks of oral DHEA therapy for postmenopausal women. Maturitas (2009) 0.86
Methodology and challenges to recruitment to a randomized, double-blind, placebo-controlled trial of oral DHEA in postmenopausal women. J Womens Health (Larchmt) (2008) 0.86
Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas (2011) 0.85
Prevalence of fecal incontinence and its relationship with urinary incontinence in women living in the community. Menopause (2011) 0.85
A pragmatic approach to the classification of menopausal status for community-based research. Menopause (2008) 0.85
Testosterone insufficiency in women: fact or fiction? World J Urol (2002) 0.84
Use of complementary and alternative medicines for menopausal symptoms in Australian women aged 40-65 years. Med J Aust (2015) 0.84
Use of a cancer registry is preferable to a direct-to-community approach for recruitment to a cohort study of wellbeing in women newly diagnosed with invasive breast cancer. BMC Cancer (2008) 0.84
Low back pain and disability in community-based women: prevalence and associated factors. Menopause (2009) 0.83
DHEA for postmenopausal women: a review of the evidence. Maturitas (2010) 0.83
The relationship between knowledge of family history and cancer characteristics at diagnosis in women newly-diagnosed with invasive breast cancer. Fam Cancer (2009) 0.83
Determinants of change in patella cartilage volume in healthy subjects. J Rheumatol (2006) 0.82
The relationship between the knee adduction moment and knee pain in middle-aged women without radiographic osteoarthritis. J Rheumatol (2006) 0.82
Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med (2008) 0.82
Endogenous estrogen and androgen levels are not independent predictors of lipid levels in postmenopausal women. Menopause (2013) 0.82
Androgens in women. J Steroid Biochem Mol Biol (2003) 0.82
The prevalence of vitamin D deficiency and relationship with fracture risk in older women presenting in Australian general practice. Australas J Ageing (2011) 0.81
The associations between the dominant and nondominant peak external knee adductor moments during gait in healthy subjects: evidence for symmetry. Arch Phys Med Rehabil (2009) 0.81
Postmenopausal testosterone therapy and breast cancer risk. Maturitas (2004) 0.81
Osteoarthritis and the postmenopausal woman: Epidemiological, magnetic resonance imaging, and radiological findings. Semin Arthritis Rheum (2004) 0.81
What is the rationale for androgen therapy for women? Treat Endocrinol (2003) 0.81
Androgenic hormones and aging--the link with female sexual function. Horm Behav (2011) 0.81
Lymphedema: experience of a cohort of women with breast cancer followed for 4 years after diagnosis in Victoria, Australia. Support Care Cancer (2013) 0.81
Breast cancer survivors' beliefs about the causes of breast cancer. Psychooncology (2011) 0.81
What is the clinical and ethical importance of incidental abnormalities found by knee MRI? Arthritis Res Ther (2008) 0.80
Endogenous androgen levels and well-being: differences between premenopausal and postmenopausal women. Menopause (2006) 0.80
Validity and cultural equivalence of the standard Greene Climacteric Scale in Hong Kong. Menopause (2010) 0.80
Persistent breast pain 5 years after treatment of invasive breast cancer is largely unexplained by factors associated with treatment. J Cancer Surviv (2013) 0.79
Lack of knowledge of hormone receptor status and use of endocrine therapy in invasive breast cancer. J Womens Health (Larchmt) (2009) 0.79
Testosterone improves antidepressant-emergent loss of libido in women: findings from a randomized, double-blind, placebo-controlled trial. J Sex Med (2014) 0.79
Association between meniscal tears and the peak external knee adduction moment and foot rotation during level walking in postmenopausal women without knee osteoarthritis: a cross-sectional study. Arthritis Res Ther (2008) 0.79
Incidence and resolution rates of different types of urinary incontinence in women: findings from a cohort study. J Urol (2011) 0.78
The role of androgen therapy. Best Pract Res Clin Obstet Gynaecol (2002) 0.78
An update on the pharmacological management of female sexual dysfunction. Expert Opin Pharmacother (2012) 0.78
Testosterone improves verbal learning and memory in postmenopausal women: Results from a pilot study. Maturitas (2011) 0.78
Testosterone aromatization and cognition in women: a randomized, placebo-controlled trial. Menopause (2006) 0.78
Patterns of use of oral adjuvant endocrine therapy in Australian breast cancer survivors 5 years from diagnosis. Menopause (2013) 0.78
A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med (2009) 0.77
Changes in patterns of use of cigarettes and alcohol in women after a first diagnosis of invasive breast cancer: a cohort study of women from Victoria, Australia. Support Care Cancer (2011) 0.77
Determining the effects of androgen therapy on sexual well-being: a complex challenge. Menopause (2005) 0.77
Androgen replacement therapy in androgen-deficient women with hypopituitarism. Drugs (2008) 0.77
Prevalence and severity of vasomotor symptoms and joint pain in women at midlife in Bangladesh: a population-based survey. Menopause (2016) 0.76
Use of imaging in surveillance of women with early stage breast cancer. ANZ J Surg (2012) 0.76
Hormonal therapies for new onset and relapsed depression during perimenopause. Maturitas (2012) 0.76
Androgen therapy in women: what we think we know. Exp Gerontol (2007) 0.76
Urinary incontinence in young nulligravid women. Ann Intern Med (2013) 0.75
Reply: To PMID 24692288. Arthritis Rheumatol (2015) 0.75
Risks of postmenopausal hormone replacement. JAMA (2002) 0.75
Sexual health consequences of premature ovarian failure. Menopause (2008) 0.75
Tibolone was associated with an increase in 7 alpha-methyl-ethinylestradiol. Menopause (2003) 0.75
Understanding female sexual function. Menopause (2009) 0.75
Psychological well-being in a cohort of women with invasive breast cancer nearly 2 years after diagnosis. Support Care Cancer (2009) 0.75
Androgens in postmenopausal women: a review. Menopause (2017) 0.75
Pharmacokinetics of a transdermal testosterone cream in healthy postmenopausal women. Menopause (2015) 0.75
Assessing sexual function in well women: validity and reliability of the Monash Women's Health Program Female Sexual Satisfaction Questionnaire. J Sex Med (2008) 0.75
Hypoactive sexual desire dysfunction in community-dwelling older women. Menopause (2016) 0.75
Comparison of effects of pravastatin and hormone therapy on soluble P-selectin and platelet P-selectin expression in postmenopausal hypercholesterolemic women. Maturitas (2006) 0.75
Measurement of total testosterone in women: comparison of a direct radioimmunoassay versus radioimmunoassay after organic solvent extraction and celite column partition chromatography. Fertil Steril (2005) 0.75
Treatment of vasomotor symptoms in the menopausal transition and postmenopausally: psychiatric comorbidity. Expert Rev Neurother (2007) 0.75
Prevalence of sexual symptoms in relation to menopause in women in Asia: a systematic review. Menopause (2017) 0.75
Postmenopausal hormone-replacement therapy. N Engl J Med (2002) 0.75